News

January 16, 2019

AbbVie, Tizona Collaborating on Development of New CD39-targeted Immunotherapies

News

AbbVie and Tizona Therapeutics are partnering to develop immunotherapies that could reshape the tumor microenvironment and enhance immune responses against cancer cells. The agreement is intended to develop new ... Read more

January 15, 2019

Scientists Discover FGL1, A Key Blocker of Immune Response Against Certain Cancers

News

A protein called FGL1 is a major inhibitory signal that blocks the immune system from fighting certain cancers, a team led by researchers at Yale Cancer Center (YCC) found. But prior ... Read more

January 11, 2019

Keytruda Receives Five New Approvals in Japan, Including 3 Expanded Uses for Lung Cancer

News

Keytruda (pembrolizumab) has simultaneously received five new approvals in Japan, including four expanded uses — three for advanced non-small cell lung cancer (NSCLC) and one for melanoma — and a new indication ... Read more

January 9, 2019

Phase 3 Trial Explores Cabometyx-Tecentriq Combo Therapy in Advanced Liver Cancer

News

A pivotal Phase 3 clinical trial testing a combination of Cabometyx (cabozantinib) with Tecentriq (atezolizumab) versus standard care of Nevaxar (sorafenib) in previously untreated patients with advanced hepatocellular carcinoma (HCC) ... Read more

January 8, 2019

Certain Brain Tumors May Respond to Immunotherapies, Other Approved Treatments

News

Most neurofibromatosis type 1 (NF1) patients with slow-growing brain tumors contain high numbers of tumor-killing immune cells, making them likely to respond to immunotherapies, a global study suggests. The study, “The ... Read more

January 4, 2019

Obesity Plays Paradoxical Role in Cancer, Study Shows

News

Obesity is known to promote cancer, but, paradoxically, obese cancer patients may respond better to cancer immunotherapy, a recent study has found. The study, “Paradoxical effects of obesity on ... Read more

January 2, 2019January 2, 2019

Celyad’s Donor-derived CAR T-cell Therapy Begins Testing in Colorectal Cancer

News

A Phase 1 trial evaluating Celyad’s CYAD-101 — a donor-derived CAR T-cell product — to treat metastatic colorectal cancer has dosed its first patient, the company announced. The trial, ... Read more

December 19, 2018December 19, 2018

Keytruda Seen as ‘Kinder’ and Superior to Standard Therapies for Advanced Head and Neck Cancer Patients in Phase 3 Trial

News

Treatment with Keytruda (pembrolizumab) extends in clinically meaningful ways the lives of people with recurrent or metastatic head and neck squamous cell carcinoma (SCC) compared to standard treatment, especially those whose tumors ... Read more

December 18, 2018

Phase 3 Trial to Test GPS Vaccine as Maintenance Therapy in High-risk Acute Myeloid Leukemia Patients

News

SELLAS Life Sciences announced plans for a newly streamlined Phase 3 trial to evaluate its investigational vaccine galinpepimut-S (GPS) as maintenance therapy for high-risk acute myeloid leukemia (AML) patients. If ... Read more

News

AbbVie, Tizona Collaborating on Development of New CD39-targeted Immunotherapies

Scientists Discover FGL1, A Key Blocker of Immune Response Against Certain Cancers

Keytruda Receives Five New Approvals in Japan, Including 3 Expanded Uses for Lung Cancer

Phase 3 Trial Explores Cabometyx-Tecentriq Combo Therapy in Advanced Liver Cancer

Certain Brain Tumors May Respond to Immunotherapies, Other Approved Treatments

Obesity Plays Paradoxical Role in Cancer, Study Shows

Top 10 Immuno-Oncology Stories of 2018

Celyad’s Donor-derived CAR T-cell Therapy Begins Testing in Colorectal Cancer

Keytruda Seen as ‘Kinder’ and Superior to Standard Therapies for Advanced Head and Neck Cancer Patients in Phase 3 Trial

Phase 3 Trial to Test GPS Vaccine as Maintenance Therapy in High-risk Acute Myeloid Leukemia Patients

Pin It on Pinterest